Metastatic EGFRm NSCLC — Osimertinib + Local Consolidative Therapy (LCT) — AstraZeneca
Visit Interactive Trial Page →
Top 10 by impressions — click to view on X
Dr. @ZPiotrowskaMD discusses NORTHSTAR #ESMO25 - impressive PFS benefit in #EGFR NSCLC when local consolidation therapy added, but notable heterogeneity. Pt...
4. #NorthStar: PhII, Osimertinib +/- local consolidative therapy (LCT)for mNSCLC EGFR+: - ⬆️ PFS w/ LCT (25.3mos vs 17.5mos, HR: 0.66) - Benefit even with polymetastatic disease -...
The long-awaited results of NORTHSTAR are finally reported at #ESMO25. @fifimcdrmh
🆙 #ELCC26 @myESMO @IASLC 🇩🇰 🔥Mini Oral session 1 ☑️NorthStar 🎯PFS Osi +/- LCT 41.5m vs. 19.6m (HR 0.43, 90%CI 0.23–0.78) 🎙️Dr. Saumil Ghandi 🎙️Chair:...
🔥 Not all EGFRm metastatic NSCLC patients benefit from LCT #ELCC26 NorthStar (LBA3) secondary analysis finally tells us who truly benefits from adding local consolidative therapy...
#NORTHSTAR update #ELCC26 1️⃣Post-osi CT @ 6-12 wks •Nodes cleared: 41.5 v 19.6 mo •Persistent: no benefit •Effusion gone: 32.7 v 22.3 mo •Persistent: no...
“Very few negatives — only positives here.” Dr. @StephenVLiu wraps up #ESMO2025 in Berlin with his expert insights on HARMONi-6, OptiTROP-Lung04 & a surprise from...
🆙 #ELCC26 @myESMO 🇩🇰 🔥Mini Oral session 1 ☑️NorthStar 🎯PFS Osi +/- LCT 41.5m vs. 19.6m (HR 0.43, 90%CI 0.23–0.78) 🎙️Dr. Saumil Ghandi 🎙️Chair: @DocSacher Dr....
Not all EGFRm NSCLC pts should get LCT #ELCC26 NorthStar (LBA3) deep dive clarifies who truly benefits from osimertinib + LCT 🧪 After 6–12 weeks induction osimertinib (no...
Addition of local RT to Osimertinib improves PFS in metastatic NSCLC ( egfr mutated ) Northstar Trial update . @myESMO #elcc26 @DrewMoghanaki @Alfdoc2...
NorthStar is a randomized phase II trial (NCT04479306) evaluating the addition of local consolidative therapy (LCT) to osimertinib in patients with EGFR-mutant metastatic NSCLC. Patients who did not progress after 6-12 weeks of induction osimertinib were randomized to continue osimertinib alone or receive osimertinib plus LCT (radiation or surgery to residual disease sites). The study addresses whether consolidating residual disease with local therapy can extend disease control beyond systemic TKI therapy alone. Primary results were presented at ESMO 2025, with updated secondary analyses at ELCC 2026.
Randomized phase II trial. Patients with EGFR-mutant metastatic NSCLC received induction osimertinib for 6-12 weeks, then those without progression were randomized 1:1 to osimertinib alone vs. osimertinib plus local consolidative therapy.
Patients with EGFR-mutant metastatic NSCLC, largely treatment-naive, including those with oligometastatic and polymetastatic disease. Patients were evaluated after induction osimertinib and only those without progression proceeded to randomization.
Osimertinib alone vs. osimertinib plus local consolidative therapy (LCT), which included radiotherapy or surgery to residual disease sites. The induction-first design allowed response assessment before LCT delivery.
Primary endpoint: progression-free survival (PFS). Secondary endpoints included patterns of failure, predictors of LCT benefit, and safety.
Addition of LCT to osimertinib significantly prolonged PFS compared with osimertinib alone. At ESMO 2025, median PFS was 25.3 months with LCT vs. 17.5 months with osimertinib alone (HR 0.66). Updated ELCC 2026 analysis in patients with nodal clearance after induction osimertinib showed median PFS of 41.5 months vs. 19.6 months (HR 0.43, 90% CI 0.23-0.78, p=0.008). Patients with persistent thoracic nodes derived no significant benefit (HR 0.93, p=0.388).
Overall survival data were not reported as mature at the time of ESMO 2025 or ELCC 2026 presentations. OS remains a key unanswered question as noted by multiple KOLs.
No new adverse events or increased risk of pneumonitis were observed with the addition of LCT. Grade 1-3 pneumonitis was reported in approximately 16% of patients in the radiation cohort. Radiotherapy technique mattered: thoracic BED of 75 Gy or higher and lung V20Gy below 25% were associated with improved outcomes and minimal toxicity.
NorthStar provides the first randomized evidence supporting local consolidative therapy added to osimertinib in EGFR-mutant metastatic NSCLC. The ELCC 2026 update critically identifies that nodal clearance and pleural effusion resolution after induction osimertinib are predictive biomarkers of LCT benefit, enabling patient selection. This remains an investigational strategy -- osimertinib is approved as monotherapy but the addition of LCT is not an approved indication.
